Gibt es eine effektive medikamentöse Prophylaxe der Ulcuskomplikationen?

  • P. Malfertheiner
Conference paper
Part of the Deutsche Gesellschaft für Chirurgie book series (DTGESCHIR, volume 1994)

Zusammenfassung

Die Vermeidung von Ulcuskomplikationen richtet sich in erster Linie auf die Verhütung von Ulcusrezidiven. Dafür stehen derzeit zwei medikamentöse Prinzipien zur Verfügung: einerseits eine Dauermedikation zur kontinuierlichen Säuresekretionshemmung, andererseits die Eradikation der H. pylori Infektion. Mit der Behandlung der H. pylori Infektion wird der natürliche Verlauf der Ulcuskrankheit entscheidend beeinflußt, indem es zur nahezu völligen Rezidivfreiheit kommt. Eine Ulcus-Sonderform wird durch die Einnahme nichtsteroidaler Antirheumatika (NSAR) bedingt. Eine Prophylaxe sollte Patienten mit erhöhtem Risiko vorbehalten werden. Bereits bestehende Ulcera heilen unter säurehemmender Therapie besser bei Absetzen der NSAR; verzögert jedoch auch unter Fortführung der NSAR Einnahme.

Schlüsselwörter

Ulcuskrankheit Säuresekretionshemmung H. pylori Infektion Eradikationstherapie 

Medical Options to Prevent Complications of Peptic Ulcer Disease

Summary

Prevention of ulcer relapse is the primary aim in order to avoid complications of ulcer disease. Two therapeutic principles are currently available for this purpose: continuous suppression of acid secretion and eradication of Helicobacter pylori. The eradication of H. pylori infection has a dramatically positive effect on the natural history of ulcer disease by minimizing the ulcer relapse rate. Ulcers induced by nonsteroidal anti-inflammatory drugs (NSAID) represent a special entity. Only patients at high risk have a benefit from prophylactic therapy. NSAID-induced ulcers heal with conventional acid inhibition treatment; they heal better if NSAID are discontinued, but delayed healing also occurs while NSAID intake is continued.

Key words

Ulcer disease Inhibition of acid secretion Helicobacter pylori infection Eradication therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Sonnenberg A (1987) Changes in physician visits for gastric and duodenal ulcer in the United States during 1958–1984 as shown by the National Disease and Therapeutic Index (NDTI). Digestive Diseases and Sciences 32:1–7PubMedCrossRefGoogle Scholar
  2. 2.
    Coggon D, Lambert P, Langmann MJS (1981) 20 years of hospital admissions for peptic ulcer in England and Wales. Lancet i: 1302CrossRefGoogle Scholar
  3. 3.
    Christensen A, Bousfield R, Christiansen J (1988) Incidence of perforated and bleeding ulcers before and after the introduction of Hk-2 receptor antagonists. Annals of Surgery 207:4–6PubMedCrossRefGoogle Scholar
  4. 4.
    Gustavsson S, Kelly KA, Melton J III (1988) Trends in peptic ulcer surgery. A population-based study in Rochester, Minnesota, 1956–1985. Gastroenterology 94:688–694PubMedGoogle Scholar
  5. 5.
    Gilinsky NH (1990) Peptic ulcer disease in the elderly. Gastroenterology Clinics of North America 19:255–271PubMedGoogle Scholar
  6. 6.
    Graham DY (1990) The relationship between nonsteroidal antiinflammatory drug use and peptic ulcer. Gastroenterology Clinics of North America 19:171–182PubMedGoogle Scholar
  7. 7.
    Bianchi Porro G, Petrillo M (1986) The natural history of peptic ulcer disease; the influence of H2–antagonist treatment. Scandinavian Journal of Gastroenterology 21 (Suppl 121): 46–52CrossRefGoogle Scholar
  8. 8.
    Dobrilla G, Vallaperta P, Amplatz S (1988) Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials. Gut 29:181–197PubMedCrossRefGoogle Scholar
  9. 9.
    Lane MR, Lee SP (1988) Recurrence of duodenal ulcer after medical treatment. Lancet i: 1147–1149Google Scholar
  10. 10.
    Holtmann GT, Armstrong D, Goebell H, Arnold R, Classen M, Fischer M and RUDER Study Group (1993) Does long-term maintenance therapy with ranitidine affect the natural course of duodenal ulcer disease? Eur J Gastroenterol & Hepatology 5:331–337Google Scholar
  11. 11.
    Lee FI, Hardman M, Jaderberg ME (1991) Maintenance treatment of duodenal ulceration: ranitidine 300 mg at night is better than 150 mg in cigarette smokers. Gut 32:151–153PubMedCrossRefGoogle Scholar
  12. 12.
    Ruszniewski PH, Slama A, Pappo M, Mignon M (1993) Two year maintenance treatment of duodenal ulcer disease with ranitidine 150 mg - a prospective multicenter randomised study. Gut 34:1662–1665PubMedCrossRefGoogle Scholar
  13. 13.
    Lauritsen K, Andersen BN, Laursen LS et al. (1991) Omeprazol 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial. Gastroenterology 100:663–669PubMedGoogle Scholar
  14. 14.
    Coghlan JG, Gilligan D, Humphries H et al. (1987) Campylobacter pylori and recurrence of duodenal ulcers: A 12–month follow-up study. Lancet ii: 1109–1111CrossRefGoogle Scholar
  15. 15.
    Marshall BJ, Goodwin CS, Warren JR et al. (1988) Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet ii: 1437–1442CrossRefGoogle Scholar
  16. 16.
    Rauws EAJ, Tytgat GNJ (1990) Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet ii: 1233–1235CrossRefGoogle Scholar
  17. 17.
    Forbes GM, Glaser ME, Cullen DJE, Warren JR, Christiansen KJ, Marshall BJ (1994) Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet 343:258–260PubMedCrossRefGoogle Scholar
  18. 18.
    Smith AC, Price AB, Borriello P, Levi AJ (1988) A comaprison of ranitidine and tripotassium dicitratobismuthate (TDB) in relapse rates of duodenal ulcer: The role of Campylobacter pylori (CP) (Abstracts) Gastroenterology 94: A 431Google Scholar
  19. 19.
    George LL, Borody TJ, Andrews P et al. (1990) Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust 153:145–149PubMedGoogle Scholar
  20. 20.
    Patchett S, Beattie S, Leen E et al. (1992) Helicobacter pylori and duodenal ulcer recurrence. Am J Gastroenterol 87:24–27PubMedGoogle Scholar
  21. 21.
    Coelho LGV, Passos MCF, Chausson Y et al. (1992) Duodenal ulcer and eradication of Helicobacter pylori in a developing country. An 18-month follow-up study. Scand J Gastroenterol 27:362–366PubMedCrossRefGoogle Scholar
  22. 22.
    Bayerdörffer E, Mannes G, Sommer A et al. (1992) Long-term follow-up after Helicobacter pylori eradication with combined omeprazole and amoxyclin treatment. Eur J Gastroenterol Hepatol 4:697–702Google Scholar
  23. 23.
    Graham DY, Lew GM, Malaty HM et al. (1992) Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102:493–496PubMedGoogle Scholar
  24. 24.
    Labenz J, Gyenes E, Tühl GH, Borsch G (1992) Amoxycillin/omeprazole cures ulcer disease associated with Helicobacter plylori infection. Am J Gastroenterol 87:1270Google Scholar
  25. 25.
    Seppälä K, Färkkilä M, Nuutinen H et al. (1992) Triple therapy of Helicobacter pylori infection in peptic ulcer. Scand J Gastroenterol 27:973–976PubMedCrossRefGoogle Scholar
  26. 26.
    Vigneri S, Termini R, Scialabba A et al. (1993) One year relapse rate after H. pylori eradication with omeprazole plus antimicrobials. Gastroenterology 10: A 220Google Scholar
  27. 27.
    Labenz J, Görsch G (1994) Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 55:19–23PubMedCrossRefGoogle Scholar
  28. 28.
    Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA (1993) Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 28:939–942PubMedCrossRefGoogle Scholar
  29. 29.
    Amstrong CP, Blower AL (1987) Nonsteroidal antiinflammatory drugs and life threatening complications of peptic ulceration. Gut 28:527–532CrossRefGoogle Scholar
  30. 30.
    Feldman M (1993) Can gastroduodenal ulcers in NSAID users be prevented? Ann Intern Med 119:337–339PubMedGoogle Scholar
  31. 31.
    Robinson MG Jr, Griffin JW, Bowers J, Kagan DG, Kugut DO et al. (1989) Effect of ranitidine on gastroduodenalmucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sei 34:424–428CrossRefGoogle Scholar
  32. 32.
    Ehsanullah RS, Page MC, Tidesley G, Wood JR (1988) Prevention of gastroduodenal damage induced by nonsteroidal antiinflammatory drugs: controlled trial of ranitidine. BMJ 297:1017–1021PubMedCrossRefGoogle Scholar
  33. 33.
    Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, Tindall E, Triadafilopoulos G, Stromatt SC, Teoh LS and Misoprostol Study Group (1993) Duodenal and gastriculcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 119:257–262Google Scholar
  34. 34.
    Lancaster-Smith MF, Jaderberg ME, Jackson DA (1991) Ranitidine in the treatment of nonsteroidal antiinflammatory drug associated gastric and duodenal ulcers. Gut 32:252–255PubMedCrossRefGoogle Scholar
  35. 35.
    Malfertheiner P (1994) Helicobacter pylori - Von der Grundlage zur Therapie. Thieme, StuttgartGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • P. Malfertheiner
    • 1
  1. 1.Medizinische KlinikUniversitätsklinik BonnBonnDeutschland

Personalised recommendations